Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

J, Xu; J, Shen; S, Gu; Y, Zhang; L, Wu; J, Wu; G, Shao; Y, Zhang; L, Xu; T, Yin; J, Liu; Z, Ren; J, Xiong; X, Mao; L, Zhang; J, Yang; L, Li; X, Chen; Z, Wang; K, Gu; X, Chen; Z, Pan; K, Ma; X, Zhou; Z, Yu; E, Li; G, Yin; X, Zhang; S, Wang; Q, Wang

doi:10.1158/1078-0432.ccr-20-2571

Public

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Shared by NobleBlocks on Oct 21, 2020 • 12:00 AM UTC

Authors:

Xu J

Shen J

Gu S

Abstract

Purpose We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).Patients and methods This nonrandomized, open-label, multicenter, phase II study enrolled pat...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!